Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma

INTERVENTION: Flticasone Frate/Vilanterol (100/25 ug) once daily Two actautions of formoterol/budesonide combinations (160/4.5 ug) twice‐daily CONDITION: Bronchial asthma PRIMARY OUTCOME: Change from baseline (0 week) in FEV1 after 8 weeks of treatment SECONDARY OUTCOME: Secondly end points are change in QOL (ACT score, ACQ score), fractional exhaled nitric oxide, forced oscillation technique and adherence after 8 weeks of treatment from baseline (0 week). Adverse events are reported throughout the study INCLUSION CRITERIA: Patients with asthma whose disease was classified as "controlled" according to the GINA criteria of asthma control under the treatment of two actuations of formoterol/budesonide combinations (160/4.5 ug) twice‐daily.